Citigroup’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-75,600
Closed -$6.43M 7806
2020
Q3
$6.43M Buy
75,600
+23,000
+44% +$1.16M ﹤0.01% 1717
2020
Q2
$1.86M Buy
52,600
+12,500
+31% +$365K ﹤0.01% 2890
2020
Q1
$541K Sell
40,100
-39,400
-50% -$663K ﹤0.01% 3806
2019
Q4
$1.68M Sell
79,500
-7,700
-9% -$136K ﹤0.01% 3187
2019
Q3
$1.16M Buy
87,200
+40,100
+85% +$589K ﹤0.01% 3483
2019
Q2
$653K Sell
47,100
-22,300
-32% -$336K ﹤0.01% 4148
2019
Q1
$1.33M Sell
69,400
-27,300
-28% -$440K ﹤0.01% 3082
2018
Q4
$1.38M Buy
96,700
+32,900
+52% +$653K ﹤0.01% 3058
2018
Q3
$1.33M Buy
63,800
+43,100
+208% +$1.02M ﹤0.01% 3167
2018
Q2
$490K Sell
20,700
-16,700
-45% -$336K ﹤0.01% 4137
2018
Q1
$546K Sell
37,400
-225,200
-86% -$3.68M ﹤0.01% 3888
2017
Q4
$4.24M Buy
262,600
+225,700
+612% +$2.66M ﹤0.01% 1987
2017
Q3
$516K Sell
36,900
-1,800
-5% -$17.9K ﹤0.01% 4094
2017
Q2
$342K Buy
38,700
+9,500
+33% +$66.7K ﹤0.01% 4341
2017
Q1
$189K Buy
29,200
+19,900
+214% +$101K ﹤0.01% 4706
2016
Q4
$34K Buy
9,300
+7,800
+520% +$23.1K ﹤0.01% 6320
2016
Q3
$5K Sell
1,500
-1,000
-40% -$2.8K ﹤0.01% 6797
2016
Q2
$6K Sell
2,500
-7,500
-75% -$25.1K ﹤0.01% 6740
2016
Q1
$25K Hold
10,000
﹤0.01% 6463
2015
Q4
$31K Buy
+10,000
New +$27.9K ﹤0.01% 6252
2015
Q3
Sell
-1,200
Closed -$5K 7913
2015
Q2
$5K Buy
+1,200
New +$4.91K ﹤0.01% 6798

Citigroup's IMMU Position: Q4 2020 in Review

Citigroup sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 568,440 shares — an estimated $48.3M sold.

Citigroup first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $48.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Citigroup reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Citigroup sold 568,440 Immunomedics Inc shares in Q4 2020, an estimated $48.3M.
  • Citigroup first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
  • Citigroup's Immunomedics Inc position peaked at $48.3M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Citigroup's 13F filing for Q4 2020, filed 11 Feb 2021.